VEGF regulation by the TSC2 tumor suppressor
TSC2 肿瘤抑制因子对 VEGF 的调节
基本信息
- 批准号:7421034
- 负责人:
- 金额:$ 17.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-05-18 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:AffectAstrocytomaBenignCellsConditionDevelopmentDiseaseDown-RegulationEnzymesExposure toGene ExpressionGene Expression RegulationGene SilencingGenesGlucoseGrowthGrowth FactorHypoxiaHypoxia Inducible FactorLinkMalignant NeoplasmsMapsMetabolicMutationNutrientOxygenOxygen measurement, partial pressure, arterialPathway interactionsPhosphorylationProtein-Serine-Threonine KinasesProteinsRegulationRenal Cell CarcinomaSignal TransductionSirolimusSiteStructureSuppressor MutationsSyndromeThinkingTissuesTranslationsTuberous sclerosis protein complexTumor SuppressionTumor Suppressor GenesTumor Suppressor ProteinsVHL proteinVascular Endothelial Growth FactorsVon Hippel-Lindau Syndromecell typeextracellulargene functionhuman TSC2 proteininsightloss of function mutationmutantprogramsreconstitutionresearch studyresponsetranscription factortumor
项目摘要
DESCRIPTION (provided by applicant):
Loss of function mutations in the Tuberous Sclerosis Complex 2 gene (TSC2) result in Tuberous Sclerosis Complex (TSC), a disease characterized by the development of tumors in many tissues.TSC2 is in a pathway that integrates extracellular signals from growth factors and nutrients with the protein translation apparatus but the contribution of this pathway to its tumor suppression function is unclear. Similarities between the cancer prone syndromes TSC and von Hippel-Lindau (resulting from mutations in the VHL tumor suppressor gene), led me to hypothesize the existence of a functional link between TSC2 and pVHL. I have now demonstrated that loss of TSC2, like loss of pVHL, results in the activation of a program of gene expression conferring a selective growth advantage to cells that is regulated by the transcription factor Hypoxia-lnducible Factor (HIF) (Brugarolas et al., 2003). TSC2 inactivation is sufficient to upregulate HIF and reconstitution of TSC2-deficient cells with a TSC2 disease-associated mutant, unlike with wild-type TSC2, fails to restore HIF regulation suggesting that this function is important for tumor suppression. Because HIF levels are normally regulated by changes in oxygen tension and this response is impaired in TSC2-deficient cells, I hypothesized that TSC2 function might also be regulated by changes in oxygen levels. Indeed, while wild-type cells downregulate mammalian Target of Rapamycin (mTOR) function in response to hypoxia, TSC2 deficient cells fail to do so, suggesting that TSC2 is required for mTOR inhibition under these conditions. Furthermore, exposure to hypoxia results in the rapid phosphorylation of TSC2. The experiments outlined in this proposal aim to unravel the mechanism whereby TSC2 function is regulated by hypoxia. A greater understanding of TSC2 regulation by hypoxia might provide insight into its function as a tumor suppressor.
描述(由申请人提供):
TSC 2基因的功能缺失突变导致了TSC 2在多种组织中发生肿瘤,TSC 2是一条整合来自生长因子和营养物质的细胞外信号与蛋白质翻译装置的途径,但该途径在其肿瘤抑制功能中的作用尚不清楚。癌症易感综合征TSC和von Hippel-Lindau(由VHL肿瘤抑制基因突变引起)之间的相似性使我假设TSC 2和pVHL之间存在功能联系。我现在已经证明,TSC 2的缺失,像pVHL的缺失一样,导致基因表达程序的激活,该基因表达程序赋予细胞选择性生长优势,该细胞由转录因子缺氧诱导因子(HIF)调节(Brugarolas等人,2003年)。TSC 2失活足以上调HIF,并且与野生型TSC 2不同,用TSC 2疾病相关突变体重建TSC 2缺陷细胞不能恢复HIF调节,这表明该功能对于肿瘤抑制很重要。由于HIF水平通常受氧张力变化的调节,而这种反应在TSC 2缺陷细胞中受损,因此我假设TSC 2功能也可能受氧水平变化的调节。事实上,虽然野生型细胞下调哺乳动物雷帕霉素靶蛋白(mTOR)功能以响应缺氧,但TSC 2缺陷型细胞不能做到这一点,表明TSC 2是在这些条件下抑制mTOR所必需的。此外,暴露于缺氧会导致TSC 2快速磷酸化。本提案中概述的实验旨在阐明TSC 2功能受缺氧调节的机制。更好地了解TSC 2通过缺氧调节可能会深入了解其作为肿瘤抑制因子的功能。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James Brugarolas其他文献
James Brugarolas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James Brugarolas', 18)}}的其他基金
Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer
解析卡博替尼抗肾癌作用机制
- 批准号:
10443836 - 财政年份:2021
- 资助金额:
$ 17.3万 - 项目类别:
Dissecting the mechanism of cabozantinib anti-tumor effect in renal cancer
解析卡博替尼抗肾癌作用机制
- 批准号:
10289979 - 财政年份:2021
- 资助金额:
$ 17.3万 - 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
9071063 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
The University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
9752982 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
University of Texas Southwestern Medical Center SPORE in Kidney Cancer
德克萨斯大学西南医学中心 SPORE 在肾癌中的应用
- 批准号:
10706530 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
Project 1: Targeting HIF2 in Renal Cell Carcinoma
项目 1:针对肾细胞癌中的 HIF2
- 批准号:
10708828 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
相似海外基金
A Phase 2 biomarker driven, Study of DB107, a Retroviral Replicating Vector, Combined With 5-FC in Patients with Recurrent Glioblastoma or Anaplastic Astrocytoma
由生物标志物驱动的 DB107(一种逆转录病毒复制载体)与 5-FC 联合治疗复发性胶质母细胞瘤或间变性星形细胞瘤患者的 2 期研究
- 批准号:
10722246 - 财政年份:2023
- 资助金额:
$ 17.3万 - 项目类别:
Multimodality Neuroimaging Evaluation of Cognitive Functioning in Lower Grade Astrocytoma
低级别星形细胞瘤认知功能的多模态神经影像评估
- 批准号:
10701775 - 财政年份:2022
- 资助金额:
$ 17.3万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10306229 - 财政年份:2021
- 资助金额:
$ 17.3万 - 项目类别:
Targeting metabolic vulnerabilities in Astrocytoma, IDH-mutant, Grade 4
针对星形细胞瘤、IDH 突变、4 级的代谢脆弱性
- 批准号:
10491830 - 财政年份:2021
- 资助金额:
$ 17.3万 - 项目类别:
metabolome analysis focusing on the malignant transformation of astrocytoma
关注星形细胞瘤恶性转化的代谢组分析
- 批准号:
19K09520 - 财政年份:2019
- 资助金额:
$ 17.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Exploring the tumorigenesis of H3F3A mutations in pediatric high-grade astrocytoma (HGA) and Giant cell tumor of the bone (GCTB).
探索儿童高级星形细胞瘤 (HGA) 和骨巨细胞瘤 (GCTB) 中 H3F3A 突变的肿瘤发生。
- 批准号:
377032 - 财政年份:2017
- 资助金额:
$ 17.3万 - 项目类别:
Fellowship Programs
A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
M032(一种表达 IL-12 的基因工程 HSV-1)在复发/进行性多形性胶质母细胞瘤、间变性星形细胞瘤或胶质肉瘤患者中的 1 期研究。
- 批准号:
9455636 - 财政年份:2017
- 资助金额:
$ 17.3万 - 项目类别:
Defining the role of the histone 3 (H3.3G34R) mutation in the pathogenesis of pediatric high grade astrocytoma
定义组蛋白 3 (H3.3G34R) 突变在儿童高级星形细胞瘤发病机制中的作用
- 批准号:
368929 - 财政年份:2017
- 资助金额:
$ 17.3万 - 项目类别:
Operating Grants
Detection and clinical application of pilocytic astrocytoma minimal residual disease
毛细胞型星形细胞瘤微小残留病的检测及临床应用
- 批准号:
16K10011 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Origin of the microvascular proliferation in pilocytic astrocytoma
毛细胞型星形细胞瘤微血管增殖的起源
- 批准号:
16K10763 - 财政年份:2016
- 资助金额:
$ 17.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




